Correlation of MET Status with Clinicopathological Features and Prognosis of Advanced Prostatic Acinar Adenocarcinoma
- VernacularTitle:进展期前列腺腺泡腺癌中MET状态与临床病理特征及预后的相关性
- Author:
Weiying HE
1
;
Wenjia SUN
1
;
Huiyu LI
2
;
Yanggeling ZHANG
1
;
De WU
1
;
Chunxia AO
2
;
Jincheng WANG
2
;
Yanan YANG
1
;
Xuexue XIAO
1
;
Luyao ZHANG
1
;
Xiyuan WANG
2
;
Junqiu YUE
1
Author Information
- Publication Type:CLINICALRESEARCH
- Keywords: c-MET; Prostate; Acinar adenocarcinoma; ADC
- From: Cancer Research on Prevention and Treatment 2025;52(8):698-704
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the correlation of MET status in patients with advanced prostatic acinar adenocarcinoma with the clinical pathological parameters and prognosis. Methods The specimen from 135 patients with advanced prostatic acinar adenocarcinoma was included. The expression of c-MET protein was detected via immunohistochemistry, and MET gene amplification was assessed by fluorescence in situ hybridization. The relationships of c-MET expression and gene amplification with clinicopathological features and prognosis were analyzed. Results The positive expression rate of c-MET was 52.60% (71/135). Compared with the c-MET expression in adjacent tissues, that in tumor tissues showed lower heterogeneous expression. Among the cases, 1.71% (2/117) exhibited MET gene polyploidy, but no gene amplification was detected. Positive c-MET expression was significantly correlated with high Gleason scores and grade groups (P=
0.0073 ). However, no significant relationship was found between c-MET expression and progression-free survival or post-treatment t-PSA levels. Conclusion c-MET protein is expressed at a relatively low level in advanced prostatic acinar adenocarcinoma, suggesting that c-MET may not be a viable target for ADC drug development in prostatic acinar adenocarcinoma.
